In a pilot study of 16 women with obesity and prediabetes, empagliflozin lowered circulating monocyte-platelet aggregates within two weeks, an effect dieting did not produce.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.